Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

‘Super pharmacy’ group snaps up PharmaDoctor in ‘seven-figure’ deal

The pharmacy group Alitam has agreed terms to merge with clinical service provider PharmaDoctor in an unspecified “seven-figure” deal, it has announced.

The merger aims to help PharmaDoctor “improve the way it delivers medical services” to the 8,000 pharmacies that subscribe to it, by providing 60 clinical services including men’s and women’s health checks, weight loss, travel, and hair loss treatment, Alitam revealed today (August 16).

This will give patients access to urgent care without an appointment in an effort to reduce waiting times for urgent and routine hospital treatments, it added.

Alitam founder and CEO Feisal Nahaboo labelled the deal the “most exciting and best merger of all” and “an industry game changer”.

Read more: ‘Super pharmacy’ CEO sets out plans for pharmacogenomics service

“We will be directly addressing the difficulty patients have in getting an urgent appointment with their GP, or at the local hospital, and substantially reducing the burden on primary healthcare as a result,” he said.

It follows a “strategic partnership” between the two companies earlier this year, allowing the Alitam group – which has over 100 branches across the UK and Ireland – to offer “walk-in, GP-type clinical services to address the chronic shortage of accessible healthcare within communities”.

 

Pharmacists “will be addressing the holistic needs of patients”

 

Bharti Patel – who joined Alitam in March as group executive director – will oversee the rollout of PharmaDoctor’s clinical services in pharmacies.

Meanwhile, Boots UK’s former head of pharmacy, Jamal Butt –  who joined Alitam in July –  and former head of Well Pharmacy Alice Hare will help support the “immediate rollout of Alitam pharmacy medical services to the UK”, the group revealed.

In a statement, Ms Patel said that the merger with PharmaDoctor will “truly leverage the abilities and skills of our pharmacists, enabling them to offer care beyond traditional prescription management”.

Read more: 'Super pharmacy' CEO: Sector is 'screaming for private investment'

They will “be addressing the holistic needs of patients, at a time when they have never needed this approach more”, she added.

“We are fully embracing all the tools PharmaDoctor has to offer, across both the electronic platforms and clinical skills training, so that we can urgently address the need for patients to receive face-to-face care,” Ms Patel said.

C+D understands that Alitam plans to announce a number of new strategic partners and mergers over the coming weeks.

In January, Mr Nahaboo unveiled an ambitious plan to create a chain of “super pharmacies” focusing on disease prevention and clinical services.

His £1 billion “Pharmacy of the Future” concept aims to bring together “a range of healthcare services under one roof” in 500 high street, “state-of-the-art wellness and medical centres” across the UK and Ireland.

 

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD136338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel